Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE
|
|
- Robert Curtis
- 5 years ago
- Views:
Transcription
1 Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria
2 Impact of Migraine Impact of migraine Unpredictable attacks Headache, associated symptoms Impaired social activities Family Peer group, friends Leisure time Impaired performance at school Absenteeism Reduced learning capacity Diagnostic aspects I History and clinical examination No routine radiological or laboratory examinations, but clear-cut indications CCT for initial evaluation of acute, possibly sinister headaches otherwise MRI plain X-rays: rarely required EEG: not indicated in migraine; only useful, if epilepsy is suspected
3 Diagnostic aspects II Consider fears and worries Parents Patient Successful migraine therapy Reduces headache duration headache frequency headache intensity Relieves associated symptoms nausea, vomiting photo- and phonophobia aura other symptoms
4 Successful migraine therapy Improves the quality of life Treatment of migraine Acute therapy Non-pharmacological Pharmacological Prophylaxis Non-pharmacological Pharmacological
5 When do we need non- pharmacological treatment? Always When do we need pharmacological treatment? Sometimes
6 Therapeutic decision I The patient's symptoms direct the decision to admininister pharmacological treatment the choice of the drug. Administering a drug without considering the patient's symptoms may cause treatment failure and other problems. Therapeutic decision II Prescribing no drug may be better than prescribing the wrong drug. There is no drug without potential risks. Even homeopathy may harm: The child learns to grab for a drug instead of acquiring appropriate coping strategies. There is no evidence that homeopathic treatment is effective in migraine and tension-type headache.
7 Migraine Non-pharmacological acute therapy Rest in darkened, quiet room Sleep Additional pharmacotherapy in patients with attacks lasting > 2 hours Pharmacological acute therapy - General aspects I Relevant pre-requisitesrequisites Diagnosis Headache duration Headache intensity Headache frequency Associated symptoms
8 Pharmacological acute therapy - General aspects II Medication as soon as possible after the onset of a migraine attack Appropriate dosage Information of the parents careful use of medication maximum dosis per day and per month time until relief of headache possible side effects Pharmacological acute therapy - General aspects III No ergots and no triptans for tensiontype headache. No treatment against the will of the patient or of the parents.
9 Pharmacological acute therapy of migraine Paracetamol/acetaminophen Ibuprofen Acetylsalicylic acid Triptans Ergots Problem: Only few controlled studies Paracetamol/Acetaminophen Clinical experience: extensive Controlled studies: yes (1+/0-) Drug of first choice Single dose: 15 mg/kg Max. daily dose: 100 mg/kg Side effects: very rare, overdosage may cause hepatic failure Contraindication: liver disease
10 Ibuprofen Clinical experience: large Controlled studies: yes (1+/0-) Drug of first choice Single dose: 10 mg/kg Max. daily dose: 40 mg/kg Side effects: gastric pain, bronchospasm, hemorrhage Contrindications: asthma, GI-ulcer Acetylsalicylic acid Clinical experience: large Controlled studies: no Drug of second choice Single dose: mg/kg Max. daily dose: mg/kg Side effects: like Ibuprofen, Reye syndrome! Contraindications: fever and viral infection in children < 12 ys., GI-ulcer, asthma
11 Nasal spray Sumatriptan Clinical experience: increasingly large Controlled studies in adolescence: yes (2+/0-) limited data in children First choice for adolescence with refractory migraine attacks Tablets, suppositories, i injections Clinical experience: some (off lable use) Controlled studies: negative or no published data Might be tried (off lable!) Further triptans I Rizatriptan Clinical experience: some (off lable) Controlled studies: yes (1+) Limited recommendation for adolescents Might be tried (off lable!)
12 Further triptans II Naratriptan, Zolmitriptan, Eletriptan, Almotriptan, Frovatriptan Clinical experience: some (off lable use) Dihydroergotamine Ergots Clinical experience: large (?) Controlled studies: yes (1+/0-) Second choice for children and adolescents with refractory migraine attacks Ergotamine tartrate Clinical experience: limited (?) Controlled studies: no Not recommended
13 Nonpharmacological prophylaxis I Reassurance and education Modification of lifestyle sufficient sleep morning free of stress regular drinks and meals sufficient breaks while studying sufficient physical exercise Nonpharmacological prophylaxis II Identification of trigger factors stress in the family stress at school learning difficulties menarche, menstruation environmental factors noise, bright lights,... physical exhaustion
14 Nonpharmacological prophylaxis III Identification of trigger factors dietary triggers often overestimated! NO RESTRICTIVE DIETS! exception: proven food intolerance Evalutation of psychiatric comorbitity Evaluation of psychosocial factors Nonpharmacological prophylaxis IV Relaxation training Biofeedback Behavioural therapy Other types of psychotherapy Possibly acupuncture
15 Pharmacological prophylaxis: General aspects Indicated in patients responding inadequately to nonpharmacological prophylaxis >1 long-lasting attack per week Consider synergistic effects and contraindications e.g. low weight, lack of appetite: use flunarizine e.g. overweight: use topiramate: Education of parents and patients Pharmacological prophylaxis: Flunarizine Controlled studies: yes (3+) Treatment of first choice Starting dose: 0.1 mg/kg/day Maintenance dose: mg/kg/day Side effects: fatigue, weight gain, depression, extrapyramidal symptoms Contraindications: Depression, obesity, extrapyramidal disorders
16 Pharmacological prophylaxis: Propranolol Controlled studies: yes (2+/2-) Treatment of first/second choice Starting dose: 0.5 mg/kg/day Maintenance dose: 1-2 mg/kg/day Side effects: fatigue, hypotension, sleep disturbance Contraindications: asthma, bradycardia, AV-block, diabetes mellitus, psoriasis Pharmacological prophylaxis: Topiramate Controlled studies: yes (1+/0-) Treatment of second choice Starting dose: 25 mg/day Maintenance dose: mg/day Side effects: paresthesia, fatigue, weight loss, difficulties to concentrate, behavioural changes
17 Pharmacological prophylaxis: Further compounds Alternative drugs (efficacy in children and adolescents not proven) valproic acid magnesium riboflavin Not recommended dihydroergotamine (low dose) acetylsalicylic acid, NSAIDS other ß-blockers Outline Genetics Neurophysiology Psychological and behavioral aspects Epidemiology Diagnosis Classification Prognosis Treatment
18 Prognosis of migraine and TTH Persisting M or TTH % Remission % Evolution from M to TTH or vice versa % Kienbacher et al., Cephalalgia 2006 Monastero et al., Neurology 2006 Prognosis of migraine and TTH Number of patients sl HA-free Kienbacher et al., Cephalalgia 2006
Management of headache
Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationHeadaches in Children and Adolescents. Paul Shillito
Headaches in Children and Adolescents Paul Shillito Topics For Discussion What s different about childhood migraine Chronic daily headache (CDH) Tumours and other things to worry about Management of childhood
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationI have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.
I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school
More informationManagement options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM
Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off
More informationVestibular Migraine. Information for patients and carers. Department of Neurology and Otolaryngology Aberdeen Royal Infirmary
Vestibular Migraine Information for patients and carers Department of Neurology and Otolaryngology Aberdeen Royal Infirmary What is vestibular migraine? Migraine is a disabling headache disorder that affects
More informationIshaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert
Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert Childhood headache: Is it really difficult to manage? It shouldn t be... But it can be...
More informationA case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:
Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants
More informationMIGRAINE A MYSTERY HEADACHE
MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)
More informationHeadaches in the Pediatric Emergency Dept
Headaches in Children February 23, 2011 Jinny Tavee, MD Associate Professor Neuromuscular Center Cleveland Clinic Foundation Cleveland, OH 1 Headaches in the Pediatric Emergency Dept Burton Gutierrez Kan
More informationAdult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationStrategies in Migraine Care
Strategies in Migraine Care Julie L. Roth, MD Rhode Island Hospital Assistant Professor, Neurology The Warren Alpert Medical School of Brown University March 28, 2015 Financial Disclosures None. Objectives
More informationAcute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor
Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor TAKE CONTROL OF YOUR MIGRAINES! ABOUT THIS PATIENT GUIDE: Migraine attacks are often debilitating
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationChronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary
Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical
More informationGoals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders
Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine
More informationMigraine in Children. Germano Falcao, MD Pediatric Neurology 03/07/2014
Migraine in Children Germano Falcao, MD Pediatric Neurology 03/07/2014 Headaches in Children One of the most common concerns reported by children 3% for children age 3-7 years 4-11% for children age 7-11
More informationFaculty Disclosures. Learning Objectives. Acute Treatment Strategies
WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received
More informationFaculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.
Faculty Disclosure Karen L. Bremer, MD Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. HEADACHE UPDATE Karen L. Bremer, MD November 10, 2017 karen.bremer@creighton.edu
More informationIndex. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.
Prim Care Clin Office Pract 31 (2004) 441 447 Index Note: Page numbers of article titles are in boldface type. A Abscess, brain, headache in, 388 Acetaminophen for migraine, 406 407 headache from, 369
More informationMaternity. Migraine in pregnancy Information for women
Maternity Migraine in pregnancy Information for women You have been given this leaflet as you have a diagnosis of migraines. It contains advice to help you manage your migraines safely during your pregnancy.
More informationMEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache
MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended
More informationHEADACHE: Benign or Severe Dr Gobinda Chandra Roy
HEADACHE: Benign or Severe Dr Gobinda Chandra Roy Associate Professor, Department of Medicine, Shaheed Suhrawardy Medical College and Hospital Outlines 1. Introduction 2. Classification of headache 3.
More informationNeurologic Disorders: Headache in Children
1 of 12 17/06/2014 7:57 PM Print Close Neurologic Disorders: Headache in Children Sharon Whiting, MBBS, FRCPC Date of revision: February 2014 Headaches occur commonly in children and adolescents. They
More informationONZETRA XSAIL (sumatriptan) nasal powder
ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.
MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am
More informationManging Migraine in Children & Adults
Manging Migraine in Children & Adults Heather Sim, Chief Executive heather.sim85@gmail.com RCN School Nurses Conference August 2017 1 What are migraines and what triggers them? How do migraines affect
More informationMIGRAINE ASSOCIATION OF IRELAND HELPLINE
MIGRAINE ASSOCIATION OF IRELAND HELPLINE 1850 200 378 1 WHAT IS MIGRAINE? Migraine is the most common neurological condition in the world, affecting about 12-15% of people. It is three times more common
More informationTriptans Quantity Limit Program Summary
Triptans Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-13,14,23,24 Agents Amerge (naratriptan) 1, 2.5 tablets Axert (almotriptan) 6.25, 12.5 tablets migraine attacks with/without
More informationSIGN on the pharmacological management of migraine
GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management
More informationAbortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL
More informationTreatments for migraine
Treatments for migraine Information for patients and carers Department of Neurology Aberdeen Royal Infirmary Contents Page About this leaflet Abortive medication for migraine Painkillers Antisickness medication
More informationPrevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.
Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology
More informationSUMAVEL DOSEPRO (sumatriptan succinate) solution for injection
SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationMigraine. What are the symptoms of a migraine attack?
Migraine Migraine causes attacks of headaches, often with feeling sick or vomiting. Treatment options include: avoiding possible 'triggers', painkillers, antiinflammatory painkillers, anti-sickness medicines,
More informationHeadache. Section 1. Migraine headache. Clinical presentation
Section 1 Headache Migraine headache 1 Clinical presentation It is important to recognize just how significant a problem migraine headache is. It has been estimated that migraine affects 11% of the United
More informationCase Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches
Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily
More informationปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา
ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา 1 CONTENT 1 2 3 Chronic Daily Headache Medical Overused Headache Management Headaches are one of the most common symptoms List
More informationChronic Daily Headaches
Chronic Daily Headaches ANWARUL HAQ, MD, MRCP(UK), FAHS DIRECTOR BAYLOR HEADACHE CENTER, DALLAS, TEXAS DISCLOSURES: None OBJECTIVES AT THE CONCLUSION OF THIS ACTIVITY, PARTICIPANTS WILL BE ABLE TO: define
More informationOH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES
1 JUSTIN A. OSSMAN, MD CHATTANOOGA FAMILY MEDICINE UPDATE OH, MY ACHING HEAD! MANAGING HEADACHE IN THE OUTPATIENT SETTING 2 I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE OBJECTIVES International
More informationUnderstanding. Migraine. Amy, diagnosed in 1989, with her family.
Understanding Migraine Amy, diagnosed in 1989, with her family. What Is a Migraine? A migraine is a recurring moderate to severe headache. The pain usually occurs on one side of the head. It is typically
More informationPaediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition
Paediatric headaches Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services Brevity, levity, repetition Paediatric)headache?)! Headache!in!children!is!not!that!common.!The!question!is!which!headaches!do!I!
More informationDubai Standards of Care (Migraine)
Dubai Standards of Care 2018 (Migraine) Preface Migraine is one of the most common problem dealt with in daily practice. In Dubai, the management of migraine is done through various different strategies.
More informationTHE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE
Rapoport Ch 05.qxd 10/15/08 1:06 PM Page 25 CHAPTER 5 THE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE ALLAN PURDY, MD, FRCPC FRED SHEFTELL, MD ALAN RAPOPORT, MD STEWART J. TEPPER, MD Case History
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationMigraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital
Migraine Management Jane Melling Headache nurse Mater Misericordiae Hospital Migraine facts Among the most common disorders of the nervous system 3 rd most prevalent medical disorder on the planet (lancet
More informationHeadache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches
Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, 2016 II. Management of Refractory Headaches Case presentation 1: A case of intractable daily-persistent headache Keio University School
More informationPharmacological treatment of attacks in juvenile migraine
J Headache Pain (2004) 5:S62 S66 DOI 10.1007/s10194-004-0110-9 Beatrice Gallai Giovanni Mazzotta Paola Sarchielli Pharmacological treatment of attacks in juvenile migraine Received: Accepted in revised
More informationTreatment of Primary Headache Syndromes
Presenter Disclosure Information 2:45 3:45pm Treatment of Primary Headache Syndromes SPEAKER Gerald W. Smetana, MD The following relationships exist related to this presentation: Gerald W.Smetana, MD,
More informationCOMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS
ACUTE THEAPIES TIPTANS TICYCLIC ANTIDEPESSANTS When starting acute treatment, healthcare professionals should warn patients about the risk of developing medication-overuse headache. ASPIIN Aspirin (900
More informationShort Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment
Clinical Highlights 1. Headache is diagnosed by history and physical examination with limited need for imaging or laboratory tests. 2. Warning signs of possible disorder other than primary headache are:
More informationHeadache Questionnaire
Date: All Headache Patients We would appreciate your cooperation in filling out this form. In our evaluation of headache, your history is typically our most valuable tool for diagnosis and subsequent treatment.
More informationHEADACHE: Types, Tips & Treatment Suggestions
Headaches are one of the most common complaints patients present with in primary care settings. They are often correlated with stress, tension and a litany of existing medical conditions. Often, patients
More informationHeadache A Practical Approach
Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:
More informationPAEDIATRIC ACUTE CARE GUIDELINE. Headache. This document should be read in conjunction with this DISCLAIMER
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in conjunction
More information10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%
PRIMARY CARE AND HEADACHE Sonja Potrebic MD PhD Regional Headache Specialist Kaiser LAMC 1 WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Column1 Primary Care 67% Primary Care Headache Specialty Other
More informationLouisiana Medicaid. Provider Update. Volume 26, Issue 4 July/August Message from the Medicaid Director Jerry Phillips
Louisiana Medicaid Provider Update Volume 26, Issue 4 July/August 2009 Message from the Medicaid Director Jerry Phillips After careful analysis of the state fiscal year 2009-2010 budget approved by the
More informationMEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache
MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache Measure Description Percentage of patients age 18 years old and older diagnosed with migraine headache whose migraine frequency is 4 migraine
More informationA synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN
A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline Scottish intercollegiate Guidelines Network SIGN November 2008. PETER FRAMPTON MSc MCOptom BAppSc (Optom)(AUS)
More informationJuly 2012 Target Population. Adult patients 18 years or older in primary care settings.
Guideline for Primary Care Management of Headache in Adults July 2012 Target Population Adult patients 18 years or older in primary care settings. Exclusions: This guideline does not provide recommendations
More informationPage: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)
Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)
More informationWhat You Should Know About Your HEADACHE. Learn more about headache types, triggers, and treatments, when to get help, and how to help yourself
What You Should Know About Your HEADACHE Learn more about headache types, triggers, and treatments, when to get help, and how to help yourself Introduction The purpose of this brochure is to give you a
More informationClinical Learning Days November 10, 2017
Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion
More information10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY
BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMigrainous headache, the menstrual cycle and pregnancy. Dr Manuela Fontebasso Headache Specialist, Author and Headache Education Facilitator
Migrainous headache, the menstrual cycle and pregnancy Dr Manuela Fontebasso Headache Specialist, Author and Headache Education Facilitator What sort of headaches? Migraine with and without aura Tension
More informationABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 12/11/2018 CLASS: Neurological Disorders REVIEW HISTORY 9/17, 12/16, 9/15, 2/15, 2/10, LOB: MCL
More informationClassification of headaches
Classification of headaches Primary headaches OR Idiopathic headaches Secondary headaches OR Symptomatic headaches THE HEADACHE IS ITSELF THE DISEASE NO ORGANIC LESION IN THE BEACKGROUND TREAT THE HEADACHE!
More informationMedication For Migraine Chart: Table 1: Acute Treatment when the attack begins
Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation
More informationTABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours
ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary
More informationUTILIZATION MANAGEMENT CRITERIA
SUMATRIPTAN (ALSUMA, IMITREX, SUMAVEL DOSEPRO, ZECUITY ) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: Serotonin 5-HT1 receptor agonists Imitrex (sumatriptan), Alsuma (sumatriptan),
More informationMigraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification
28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification
More informationErgotamine/Dihydroergotamine Products
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSpecific Care Question : Question Originator: Plain Language Summary from The Office of Evidence Based Practice: Conditional Recommendation
Ketorolac for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine is ketorolac an effective treatment? Question Originator: Migraine Therapy
More informationMigraine. A booklet for people with migraine and their carers. Consultation. Consultation. draft. draft. Scottish guidelines
Migraine Scottish guidelines A booklet for people with migraine and their carers Cover image courtesy of Migraine Action (migraineart.org.uk) Patient quotes kindly supplied by The Migraine Trust Scottish
More informationMigranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: June 22, 2017 Migranal Nasal Spray
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPediatric Headache Diary
Patient Name Age Pediatric Headache Diary Day of week Date Time of onset Duration (hours/minutes/days) Location (forehead, temples, back of head, generalized, etc.) Type of pain (throbbing, piercing, tight
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 11 Oxytocics and Ergot Alkaloids. LESSON ASSIGNMENT Paragraphs 11-1 through 11-13. LESSON OBJECTIVES After completing this lesson, you should be able to: 11-1. Given a group of
More informationCHRONIC HEADACHES IN CHILDHOOD
CHRONIC HEADACHES IN CHILDHOOD EDWIN LIU, MD PEDIATRIC NEUROLOGISTS OF PALM BEACH PEDIATRIC SLEEP CENTERS OF FLORIDA ASSISTANT CLINICAL PROFESSOR FSU ASSISTANT CLINICAL PROFESSOR NOVA SOUTHEASTERN PEDIATRIC
More informationWelcome to MedWell. Patient Information. Name: Address: City: State: Zip Code: !Other. Name: Address: City: State:
1 Welcome to MedWell Patient Information Date: Name: Date of Birth: / / Address: City: State: Zip Code: Home Phone: ( ) - Cell Phone: ( ) - Email: Gender:! Male! Female Last 4 of Social Security Number
More informationOptimizing triptan therapy in clinical practice
Review Optimizing triptan therapy in clinical practice Carlo Lisotto* & Giorgio Zanchin Practice Points The prevalence of migraine is 12 16% of the general population and is two- to threetimes higher in
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 8/29/06 Triptans: almotriptan, Amerge, Axert, Frova,
More informationHeadache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology
Headache and Facial Pain Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology Introduction It is the most common neurologic complain The diagnosis usually
More informationCYCLIC VOMITING SYNDROME. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis
CYCLIC VOMITING SYNDROME C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis Case 26 year old male Symptoms began at age 19 yr 5-6 day episodes of recurrent, severe vomiting
More informationTriptan Quantity Limit
*- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5
More informationNeurosurgery Associates Headache Intake Questionnaire
Neurosurgery Associates Headache Intake Questionnaire 393 E Town Street, Suite 110 Columbus, OH 43215 First Name: Last Name : Date of Birth: Age: Referring Doctor: Pharmacy: Primary Insurance: Place of
More informationHeadaches in Children
How common are headaches? What is the impact? Very common! 20% of kids from preschool through teenage report frequent or severe headaches in any given year 2 Headaches are more common in children who have
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationCOLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE
COLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE HEADACHE CHARACTERISTICS Frequency and Severity 1. At what AGE did you get your first headache, of ANY kind? 2. At what AGE did your headaches
More informationOveruse of barbiturate and opioid containing medications for primary headache disorders Description
Measure Title Overuse of barbiturate and opioid containing medications for primary headache disorders Description Percentage of s age 12 years and older with a diagnosis of primary headache who were prescribed
More informationRegulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: November 30, 2018 Migranal Nasal Spray
More informationMIGRAINE ASSOCIATION OF IRELAND
MIGRAINE ASSOCIATION OF IRELAND HEADACHE IN MEN: THE FACTS This leaflet was composed by Paolo Rossi M.D., Ph.D. of the European Headache Alliance to mark European Migraine Day of Action 2014. Why a leaflet
More informationNB Drug Plans Formulary Update
Bulletin #980 August 23, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective August 23, 2018. Included in this bulletin: Regular Benefit Additions Special
More informationAnti-Migraine Agents
DRUG POLICY BENEFIT APPLICATION Anti-Migraine Agents Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationAdolescent Migraine Treatment O F A
Adolescent Migraine Treatment M A R C Y Y O N K E R, M D F A H S D I R E C T O R, P E D I A T R I C H E A D A C H E P R O G R A M A S S O C I A T E P R O F E S S O R, C H I L D H E A L T H, U O F A Goals
More informationDrug Class Review on the Triptans
Drug Class Review on the Final Report March 7, 2003 Expires October 31, 2003 Mark Helfand, MD, MPH Kim Peterson, MS Produced by Oregon Health & Science University 3181 SW Sam Jackson Park Road Mailcode:
More information